📊 NUS Key Takeaways
Is NUS a Good Investment? Thesis Analysis
Nu Skin demonstrates solid profitability with strong margins (69.4% gross, 10.8% net) and healthy ROE/ROA, but faces significant headwinds from 14.3% revenue decline YoY, indicating market challenges or structural demand issues. The dramatic net income surge (+209.3% YoY) appears driven by non-operational items rather than sustainable business growth, warranting cautious evaluation of earnings quality.
Why Buy NUS? Key Strengths
- Exceptionally high gross margin of 69.4% indicates strong pricing power and cost management
- Solid balance sheet with 2.08x current ratio, 0.25x debt/equity, and adequate liquidity (238.6M cash)
- Strong returns on equity (19.9%) and assets (11.4%) demonstrate efficient capital deployment
- Healthy interest coverage of 3.2x indicates manageable debt burden
NUS Investment Risks to Consider
- Significant 14.3% YoY revenue decline suggests serious headwinds in core business or market saturation in wellness/beauty sector
- Operating margin of only 4.4% is concerning given 69.4% gross margin, indicating operational inefficiency or high SG&A expenses
- Net income surge (+209.3% YoY) disconnected from revenue trend raises quality-of-earnings concerns; likely one-time gains or tax benefits
- Free cash flow margin of only 3.1% despite double-digit net margins indicates potential working capital or capex pressures
- 21 Form 4 insider filings in 90 days may indicate high turnover or potential shareholder concerns
Key Metrics to Watch
- Revenue trend reversal - critical to confirm if decline stabilizes or accelerates
- Operating margin expansion - must improve substantially given margin degradation vs. gross profit
- Operating cash flow sustainability - free cash flow must normalize relative to net income
- Gross margin stability - key competitive advantage that must be protected
- Debt reduction progress - opportunity to optimize capital structure given conservative leverage
NUS Financial Metrics
💡 AI Analyst Insight
The relatively thin 3.1% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.08x current ratio provides a solid financial cushion.
NUS Profitability Ratios
NUS vs Default Sector
How NU SKIN ENTERPRISES, INC. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NUS Overvalued or Undervalued?
Based on fundamental analysis, NU SKIN ENTERPRISES, INC. has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NUS Balance Sheet & Liquidity
NUS 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: NU SKIN ENTERPRISES, INC.'s revenue has declined by 27% over the 5-year period, indicating business contraction. The most recent EPS of $0.17 reflects profitable operations.
NUS Growth Metrics (YoY)
NUS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $364.2M | $8.3M | $0.17 |
| Q2 2025 | $386.1M | $21.1M | $0.43 |
| Q1 2025 | $364.5M | -$533.0K | $-0.01 |
| Q3 2024 | $430.1M | $1.3M | $0.03 |
| Q2 2024 | $439.1M | $26.9M | $0.54 |
| Q1 2024 | $417.3M | -$533.0K | $-0.01 |
| Q3 2023 | $498.8M | $1.3M | $0.03 |
| Q2 2023 | $500.3M | $26.9M | $0.54 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NUS Capital Allocation
NUS SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for NU SKIN ENTERPRISES, INC. (CIK: 0001021561)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NUS
What is the AI rating for NUS?
NU SKIN ENTERPRISES, INC. (NUS) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NUS's key strengths?
Claude: Exceptionally high gross margin of 69.4% indicates strong pricing power and cost management. Solid balance sheet with 2.08x current ratio, 0.25x debt/equity, and adequate liquidity (238.6M cash).
What are the risks of investing in NUS?
Claude: Significant 14.3% YoY revenue decline suggests serious headwinds in core business or market saturation in wellness/beauty sector. Operating margin of only 4.4% is concerning given 69.4% gross margin, indicating operational inefficiency or high SG&A expenses.
What is NUS's revenue and growth?
NU SKIN ENTERPRISES, INC. reported revenue of $1.5B.
Does NUS pay dividends?
NU SKIN ENTERPRISES, INC. pays dividends, with $11.8M distributed to shareholders in the trailing twelve months.
Where can I find NUS SEC filings?
Official SEC filings for NU SKIN ENTERPRISES, INC. (CIK: 0001021561) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NUS's EPS?
NU SKIN ENTERPRISES, INC. has a diluted EPS of $3.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NUS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, NU SKIN ENTERPRISES, INC. has a HOLD rating with 62% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NUS stock overvalued or undervalued?
Valuation metrics for NUS: ROE of 19.9% (sector avg: 15%), net margin of 10.8% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy NUS stock in 2026?
Our dual AI analysis gives NU SKIN ENTERPRISES, INC. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NUS's free cash flow?
NU SKIN ENTERPRISES, INC.'s operating cash flow is $80.3M, with capital expenditures of $34.3M. FCF margin is 3.1%.
How does NUS compare to other Default stocks?
Vs Default sector averages: Net margin 10.8% (avg: 12%), ROE 19.9% (avg: 15%), current ratio 2.08 (avg: 1.8).